Nanox Expands U.S. Distribution Network For Nanox.ARC Across New England

Nanox Imaging Ltd (NASDAQ: NNOX) said its subsidiary Nanox AI entered an exclusive UK sales reseller agreement with Vertec Scientific for commercialization of Nanox.AI bone solution (HealthOST). The initial three-year term requires Vertec to meet minimum annual license commitments. HealthOST is FDA-cleared and UKCA/CE-marked and was recommended by NICE in Nov 2025 for NHS use.

Nanox Imaging (NASDAQ: NNOX) said it signed an exclusive distribution agreement with Top Med SAC for Peru to deploy the Nanox.ARC system and related services. Top Med will handle regulatory approvals, marketing, installation, maintenance, training and support. The deal is a capex model with an initial expected deployment of six systems, subject to permits.

Xenon Pharmaceuticals (XENE) will present data on azetukalner, a potential epilepsy treatment, at the European Epilepsy Congress. The company reported a net loss of $110.7M in Q2 2026, up from $84.7M a year earlier, due to increased R&D and administrative costs. Xenon expects to file for FDA approval of azetukalner in Q3 2026 and is also testing the drug for depression and pain.

Teledyne Technologies (NYSE:TDY) announced a $21M contract for PHOENIX-XR weapon sights with Germany's Bundeswehr, part of a $175M framework agreement. This brings total deliveries to over 1,000 units, reinforcing Teledyne Qioptiq's leadership in Europe for ITAR-free cooled thermal weapon sights.

The Pentagon reports that the costs of all three F-35 variants have increased by up to 11 percent. The F-35A's average flyaway cost rose to $92 million, the F-35B to $121.4 million, and the F-35C to $110.8 million. Lockheed Martin attributes the increases to modernization and supply chain issues. The total lifecycle costs of the F-35 program are now projected to be below $2 trillion.

Tesla unveiled its Cybercab driverless robotaxi after market close on Thursday. Analysts from Seeking Alpha shared their views on the impact of this new vehicle. The event took place in Austin, Texas. Investors may consider the analysts' perspectives on Tesla's latest development.